Arun Rajan, M.D.
Phase Ib multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignanciesOpen - RecruitingNCI Protocol ID NCI-17-C-0176Investigator Arun Rajan, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Yvonne Mallory 240 760-6116
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based ChemotherapyOpen - RecruitingNCI Protocol ID NCI-17-C-0066Investigator Arun Rajan, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Arlene Berman 301-435-5609
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial..Lancet Oncol.. 18(5): 599-610., 2017. [ Journal Article ]
- Lun Cancer. 101: 104-110, 2016. [ Journal Article ]
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial..Lancet Oncol.. 16(2): 177-86, 2015. [ Journal Article ]
- J Thorac Oncol. 9(9 Suppl 2): S131-S136, 2014. [ Journal Article ]
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial..Lancet Oncol. . 15(2): 191-200., 2014. [ Journal Article ]
Dr. Rajan received his M.B.B.S. and M.D. degrees from the University of Delhi, New Delhi, India, in 1998 and 2002, respectively. He then joined the State University of New York in Syracuse, where he completed his internal medicine residency training in 2005, followed by fellowship training in hematology and medical oncology, which he completed in 2008. In July 2008, Dr. Rajan joined the Thoracic Oncology Section of the Medical Oncology Branch. His work focuses on developing new therapies for patients with lung cancer and thymic malignancies. Dr. Rajan also serves as the course coordinator for the clinical elective program in medical oncology and organizes the bi-monthly multidisciplinary thoracic oncology tumor board meeting.